Azenta Inc To Host Investor Day Transcript

The following is excerpted from the question-and-answer section of the transcript.

Question: Matthew Stanton - Jefferies LLC - Analyst : Matt Stanton from Jefferies. Maybe just to zoom in on two of the buckets on the revenue bridge. First, the growth initiatives, you talked about biorepositories, digital, gene synthesis. Can you just talk about your confidence in line of sight into some of these bigger areas of that bucket, and then any investments needed? And then also on new product introductions, it sounds like that's more of a late '27, '28 story. But with the focus on C&I and Multiomics, just talk about some of the items you're most excited about and what you and the team are doing differently today versus prior around R&D.

Question: Matthew Stanton - Jefferies LLC - Analyst : Thanks. And then on the regionalization of gene synthesis, maybe just a bit more color in terms of investment required here, timing and cadence. Is that in flight now? And then I guess just a little more on how that helps you. It feels like you have a pretty good line of sight and confidence around meeting local demand, improving turnaround times. But just talk a little bit more around the initiatives there. And then, Lawrence, maybe if you could just talk, too, about being able to protect the margin structure as you move capacity into the US and into Europe as well on gene synthesis.